Gold bars to be exempt from tariffs, White House clarifies
Investing.com - Collegium Pharmaceutical (NASDAQ: COLL) reported second quarter EPS of $1.68, $0.02 better than the analyst estimate of $1.66. Revenue for the quarter came in at $188M versus the consensus estimate of $182.69M.
Guidance
Collegium Pharmaceutical sees FY 2025 revenue of $745.00M-$760.00M versus the analyst consensus of $745.80M.
Collegium Pharmaceutical’s stock price closed at $29.75. It is up 2.98% in the last 3 months and down -15.77% in the last 12 months.
Collegium Pharmaceutical saw 1 positive EPS revisions and 3 negative EPS revisions in the last 90 days. See Collegium Pharmaceutical’s stock price’s past reactions to earnings here.
According to InvestingPro, Collegium Pharmaceutical’s Financial Health score is "great performance".
Check out Collegium Pharmaceutical’s recent earnings performance, and Collegium Pharmaceutical’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar